Lupin has acquired Huminsulin®in India from Eli Lilly and Company (Lilly) to enhance its diabetes portfolio. The Huminsulin range, including Insulin Human, is used for treating type 1 and type 2 diabetes mellitus to improve blood sugar control in adults and children. Insulin treatment is crucial for type 1 diabetes management and often becomes necessary over time in type 2 diabetes.

Lupin has been marketing the Huminsulin range through existing Distribution and Promotion Agreements with Lilly, India. The significant Indian population affected by diabetes is prescribed InsulinHuman for management alongside other concomitant therapies.

“This acquisition is critical to our ongoing efforts to expand our diabetes portfolio and provide high-quality, cost-effective health care to our patients. It reinforces our unwavering commitment to combating diabetes and providing comprehensive care” said Nilesh Gupta, Lupin’s Managing Director.

Regarding the acquisition, Rajeev Sibal, President – of India Region Formulations, Lupin, said, “Lupin has been at the forefront of providing holistic diabetic care to patients. This acquisition expands our diabetes portfolio and allows us to provide a diverse variety of human insulin choices to millions of patients, allowing them to live better lives”.

A great acquisition indeed.

Priyanka Dutta